In conclusion, the represented data suggests that the loss/lack of achievement of MMR in TKI-treated CP CML coincides with the occurrence of circulating CD34+ progenitor cells with elevated separase activity. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.